Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.
about
Role of insulin in the type 2 diabetes therapy: past, present and futureUse of insulin pumps in India: suggested guidelines based on experience and cultural differencesAccuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies.Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3.Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus.Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.Changing trends in management of gestational diabetes mellitus.Cross-sectional survey and retrospective analysis of a large cohort of adults with type 1 diabetes with long-term continuous subcutaneous insulin infusion treatmentChanges in Insulin Requirements From the Onset of Continuous Subcutaneous Insulin Infusion (CSII) Until Optimization of Glycemic Control.Efficacy of Insulin Pump Therapy on Diabetes Treatment Satisfaction and Glycemic Control Among Patients with Type 1 Diabetes Mellitus in Saudi Arabia: A Prospective StudyDo We Need Updated Guidelines on the Use of Insulin Pump Therapy in Type 2 Diabetes? A Review of National and International Practice Guidelines.Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events: Results From a Prospective Randomized Crossover Study.Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulin.Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabeteImpact of insulin pump on quality of life of diabetic patients.Diabetes Technology: Uptake, Outcomes, Barriers, and the Intersection With Distress.Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend studyClinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial.Artificial pancreas: an emerging approach to treat Type 1 diabetes.Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production.Intensifying treatment of type 2 diabetes mellitus: adding insulin.Management of diabetes mellitus: is the pump mightier than the pen?Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusionNew technologies for diabetes: a review of the present and the future.Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.Insulin therapy versus cell-based therapy for type 1 diabetes mellitus: what lies ahead?Availability of insulin pump therapy in clinical practice.A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation.Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus.Experiences and decision making during paediatric transitions to continuous sub-cutaneous insulin infusion (CSII): A mixed method studyA Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
P2860
Q22241148-2306836D-0A1A-43F9-8007-C46FEAB206B0Q24630480-BFC86111-C296-4B2A-BC7B-41940555803EQ30653146-CFC3CFFF-4A1B-4D25-8ABA-2C69FAA74207Q34018165-464E439E-B386-4818-A4A7-535E864F6F42Q34068043-FD8611FA-C168-473E-AFA2-5A179CEED010Q34449270-2CFC25F8-FF92-49BA-A27C-28C297220686Q35179234-E12D2FF9-452B-4D20-A080-EF1D16A47FB7Q35682636-D81412E2-2F47-4EC2-9D47-E6515586E69AQ35682701-6C980580-C033-4A29-B867-568D93ABB21EQ35772599-272A65C6-4D59-4A68-ABE5-092709549979Q36130870-B6D86124-8357-418A-A517-1AE474783671Q36340429-6B33A956-148E-437D-9AA9-DF8E248A1C7FQ36792962-4AA060E3-58FA-42B6-A36C-EE7A4CDB5A66Q36869489-543F607F-E67D-488B-AFE2-88B256CB1A5DQ37015613-1B6B60F8-A51D-4E4F-9CE5-F8AD80F747D4Q37054720-3378194F-18C1-4215-A757-567F9264FF6EQ37437141-3F2E4EFC-C410-42CD-96A8-B4AA360449E3Q37492413-FBA47A4A-E67A-4CBF-84E8-95167B88DBE3Q37538736-BCD09563-D79D-47EC-A21C-6AD325211DE3Q37715598-999BC8ED-9313-434F-A8D8-197365FC72BBQ37961849-44BF3B2F-E9B5-4558-8E77-C4A936B49978Q37988797-078997E1-1763-45ED-90D3-3A2817E0DD88Q38037730-26F4897A-D62A-4658-9B1B-4E983DF7591BQ38055490-33A2B374-B3CF-4AB5-A805-213C4410FDFCQ38804719-930A8603-EBDF-40CB-A5AA-000072A87896Q38845574-A4CDFE91-0E89-465D-B372-4DAADE49D422Q42549612-7B602831-BA78-49EA-A855-0AAF7E04B23DQ44047825-1DFAB26F-A027-4947-B6BD-C1C9C408D115Q52666804-25192AFC-9B3E-4C17-93B4-1F98DAA3A356Q53489843-C56DAF91-497F-4531-AD5B-7459DCAEEA7FQ58595071-588E00F0-6C9E-460F-BD7A-BA7F5EDCCDA2Q58699251-8B91A8EA-A68B-436B-B4F4-9CDFCF708507
P2860
Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@en
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@nl
type
label
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@en
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@nl
prefLabel
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@en
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@nl
P921
P356
P1433
P1476
Long-acting insulin analogs ve ...... of type 1 and type 2 diabetes.
@en
P2093
Eric Renard
John C Pickup
P304
P356
10.2337/DC08-S235
P407
P478
31 Suppl 2
P577
2008-02-01T00:00:00Z